title: Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk.
abstract: BACKGROUND
  Psoriasis is a chronic skin disorder which negatively impacts a patient's quality of life (QoL). A recently published assessment tool, PsoDisk, has been proposed to evaluate patient's QoL.
  
  
  OBJECTIVE
  The aim of this study was to test PsoDisk as a QoL assessment tool in psoriatic patients undergoing treatment with adalimumab.
  
  
  METHODS
  A retrospective, monocentric study, including patients who completed at least 48 weeks of both adalimumab therapy and PsoDisk assessment. PASI was assessed by the physician whereas the PsoDisk test was self-performed by the patient. Both were evaluated at each control visit throughout the study-period in order to detect changes in disease severity and the impact of quality of life, respectively.
  
  
  RESULTS
  In total, we evaluated 31 patients selected from our database. At baseline, all aspects of patients' psycho-emotional and social lives were impaired. PASI score reduction correlated with a PsoDisk score decrease (r = 0.97; p = 0.02), reflecting an overall improvement of patient's QoL.
  
  
  CONCLUSIONS
  PsoDisk was found to be easy to administer and intuitive for interpreting clinical results.
authors.affiliation: Department of Dermatology, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Chiricozzi
authors.affiliation: Department of Dermatology, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Bianchi
authors.affiliation: Department of Dermatology, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
authors.forename: Arianna
authors.initials: A
authors.lastname: Zangrilli
authors.affiliation: Department of Dermatology, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
authors.forename: Mauro
authors.initials: M
authors.lastname: Bavetta
authors.affiliation: Department of Dermatology, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Giunta
authors.affiliation: Department of Dermatology, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
authors.forename: Sergio
authors.initials: S
authors.lastname: Chimenti
authors.affiliation: Department of Dermatology, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
authors.forename: Rosita
authors.initials: R
authors.lastname: Saraceno
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology*; D011594:Psychometrics / Q000379:methods*; D011788:Quality of Life; D012189:Retrospective Studies; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000068879:Adalimumab
keywords: Psodisk; adalimumab; biologicals; psoriasis; quality of life